TRPM3 and myalgic encephalomeyelitis/chronic fatigue syndrome: Even if new evidence indicates that LDN can improve daily function and quality of life in ME/CFS patients, further in vitro investigation is needed to understand the underlying regulatory mechanisms involving TRPM3 and opioid receptors in NK cells to help understand the pathomechanism of ME/CFS and identify therapeutic targets.